Anagenex is a technology company.
Anagenex has raised $30.0M across 1 funding round.
Anagenex has raised $30.0M in total across 1 funding round.
Anagenex has raised $30.0M in total across 1 funding round.
Anagenex's investors include ARCH Venture Partners, Catalio Capital, Kiersten Stead, Dimension Capital.
Anagenex is a biotechnology company specializing in AI-driven drug discovery for the biopharmaceutical industry. It develops a precision small molecule discovery platform that uses generative AI to design compounds, custom chemistry to synthesize up to 100 million target-specific molecules for testing in two weeks, and high-throughput experiments to identify and modulate disease-associated proteins, particularly for intractable targets in synthetic lethal oncology.[1][3]
The company serves pharmaceutical research and development sectors by accelerating the discovery of first-in-class and best-in-class small molecule medicines. Founded in 2019 and headquartered in Lexington, Massachusetts, Anagenex has raised $45.9M in total funding, including a $38.7M Series A round three years ago, and remains at the Series A stage with a focus on pre-clinical innovation.[1]
Anagenex was founded in 2019 by Nicolas Tilmans, its first-time CEO with scientific ambitions to disrupt small molecule drug discovery at scale.[1][2] Early on, the company lacked organizational structure and significant funding; Tilmans engaged Occam Global for strategic guidance on board construction and executive recruitment to build a framework for growth.[2]
Pivotal moments included recruiting Tito Serafini as Board Chair, an experienced biotech CEO, and Joe Franklin to lead DNA-encoded library (DEL) creation and scale R&D infrastructure. This was followed by Ryan Kruger as Chief Scientific Officer in 2023 and Adrian Schreyer as Chief Technology Officer in 2024, enabling the company to advance its machine learning-driven platform.[2] In July 2024, Anagenex announced its first programs in a synthetic lethal oncology franchise, marking a key step in pipeline development.[1]
Anagenex stands out in AI-powered drug discovery through these key strengths:
Anagenex rides the explosive growth of generative AI in healthcare and life sciences, particularly AI-powered drug discovery for pharma, as highlighted in market maps and trend reports.[1] Its timing aligns with surging demand for faster, cheaper small molecule development amid rising oncology needs and challenges in targeting "undruggable" proteins—market forces amplified by big pharma's shift to AI partnerships for efficiency.
By influencing the ecosystem through pre-clinical breakthroughs, Anagenex contributes to a paradigm shift from traditional screening to data-driven evolution, potentially lowering costs and timelines while expanding treatable targets, as seen in its mentions in expert analyses up to March 2025.[1]
Anagenex is poised to advance its synthetic lethal oncology pipeline toward clinical milestones, leveraging its AI-lab feedback loop for rapid iterations on high-value targets. Trends like expanding AI-biotech collaborations and oncology precision medicine will propel it, potentially attracting further funding or partnerships despite a recent Mosaic Score dip signaling market pressures.[1]
Its influence may evolve by pioneering scalable directed evolution, setting a template for next-gen drug hunters—echoing its founding mission to transform biopharma R&D from the ground up.
Anagenex has raised $30.0M across 1 funding round. Most recently, it raised $30.0M Series A in June 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2022 | $30.0M Series A | ARCH Venture Partners, Catalio Capital, Kiersten Stead, Dimension Capital |